Initial


Journal

Pediatric hematology and oncology
ISSN: 1521-0669
Titre abrégé: Pediatr Hematol Oncol
Pays: England
ID NLM: 8700164

Informations de publication

Date de publication:
Feb 2021
Historique:
pubmed: 18 8 2020
medline: 3 6 2021
entrez: 18 8 2020
Statut: ppublish

Résumé

Eltrombopag is a small molecule, thrombopoietin receptor agonist approved for the treatment of patients with aplastic anemia and chronic immune thrombocytopenia. It is also a polyvalent cation chelator and inhibits leukemia cell proliferation via reduction of intracellular iron. The

Identifiants

pubmed: 32804009
doi: 10.1080/08880018.2020.1802539
pmc: PMC8670012
mid: NIHMS1761983
doi:

Substances chimiques

Bacterial Outer Membrane Proteins 0
Benzoates 0
Escherichia coli Proteins 0
Hydrazines 0
Multienzyme Complexes 0
Pyrazoles 0
envZ protein, E coli EC 2.7.3.-
eltrombopag S56D65XJ9G

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

8-13

Subventions

Organisme : NCI NIH HHS
ID : U01 CA199221
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA199222
Pays : United States

Références

Stem Cell Res. 2012 Sep;9(2):77-86
pubmed: 22683680
Int J Hematol. 2017 Dec;106(6):765-776
pubmed: 28864871
Leuk Res. 2011 Mar;35(3):323-8
pubmed: 20688394
Pediatr Clin North Am. 1997 Aug;44(4):973-89
pubmed: 9286295
Cancer Treat Rev. 2014 May;40(4):523-32
pubmed: 24345772
N Engl J Med. 2012 Jul 5;367(1):11-9
pubmed: 22762314
Blood. 2009 Oct 29;114(18):3899-908
pubmed: 19710504
Pediatr Blood Cancer. 2007 Dec;49(7):928-40
pubmed: 17066459
N Engl J Med. 2007 Nov 29;357(22):2237-47
pubmed: 18046028
Blood. 2018 Dec 20;132(25):2629-2638
pubmed: 30305280
Lancet Haematol. 2019 Mar;6(3):e122-e131
pubmed: 30704923
Biochim Biophys Acta. 2009 Jul;1790(7):702-17
pubmed: 18485918
Expert Rev Anticancer Ther. 2018 Jan;18(1):39-50
pubmed: 29210294
Blood. 2017 Oct 26;130(17):1923-1933
pubmed: 28864815
Cell Rep. 2019 Nov 5;29(6):1675-1689.e9
pubmed: 31693904
N Engl J Med. 2018 Oct 25;379(17):1643-1656
pubmed: 30354958
Cancer Invest. 2005;23(8):683-91
pubmed: 16377587
Curr Opin Hematol. 2012 Sep;19(5):392-8
pubmed: 22872157
Blood. 2012 Jul 12;120(2):386-94
pubmed: 22627766

Auteurs

Grace Nevil (G)

Division of Pediatric Oncology, MD Anderson Children's Cancer Hospital, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Michael Roth (M)

Division of Pediatric Oncology, MD Anderson Children's Cancer Hospital, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Jonathan Gill (J)

Division of Pediatric Oncology, MD Anderson Children's Cancer Hospital, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Wendong Zhang (W)

Division of Pediatric Oncology, MD Anderson Children's Cancer Hospital, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Beverly Teicher (B)

National Cancer Institute, Bethesda, maryland, USA.

Stephen W Erickson (SW)

RTI International, Research Triangle Park, North Carolina, USA.

Gregory Gatto (G)

RTI International, Research Triangle Park, North Carolina, USA.

Malcom Smith (M)

National Cancer Institute, Bethesda, maryland, USA.

E Anders Kolb (EA)

Division of Pediatric Hematology/Oncology, A.I. duPont Hospital for Children, Wilmington, Delaware, USA.

Richard Gorlick (R)

Division of Pediatric Oncology, MD Anderson Children's Cancer Hospital, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH